{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-032116","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.314876+00:00","generated_at":"2026-05-15T09:40:04.208587+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Humacyte announces $20M registered direct offering of 25M shares at $0.80/share","bullets":["Gross proceeds of $20M from 25M shares at $0.80; net proceeds ~$18.4M after fees.","Offering led by a new life science dedicated investor and a long-only mutual fund.","Net proceeds to fund Symvess commercialization, hemodialysis Phase 3 read-out, and pipeline.","Expected to close March 20, 2026, subject to customary closing conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-032116","json":"https://secwatch.observer/filing/0001104659-26-032116.json","markdown":"https://secwatch.observer/filing/0001104659-26-032116.md","text":"https://secwatch.observer/filing/0001104659-26-032116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/0001104659-26-032116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/tm269106d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:40:04.208587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"052a68944d99d6c028b55baac68c0eca6ad05b5d","claim":"Humacyte, Inc. entered into Placement Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2026-03-19).","evidence_excerpt":"On March 19, 2026, the Company also entered into a placement agent agreement (the “Placement Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as the placement agent (the “Placement Agent”), in connection with the Offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/0001104659-26-032116-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Titan Partners Group LLC, a division of American Capital Partners, LLC"},{"label":"Effective","value":"2026-03-19"}]},{"claim_id":"36c52806f6b4ba76789879337a75300a411e2be9","claim":"Humacyte, Inc. entered into Purchase Agreements with certain investors valued at 25,000,000 shares ... at a price of $0.80 per share (effective 2026-03-19).","evidence_excerpt":"On March 19, 2026, Humacyte, Inc. (the “Company”) entered into certain securities purchase agreements (the “Purchase Agreements”) pursuant to which the Company agreed to issue and sell to certain investors in a registered direct offering (the “Offering”) 25,000,000 shares of the Company’s common stock, $0.0001 par value per share, at a price of $0.80 per share (the “Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/0001104659-26-032116-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"25,000,000 shares ... at a price of $0.80 per share"},{"label":"Effective","value":"2026-03-19"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}